Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis

Table 1 Incidence of stroke in SCD patients on hydroxyurea therapy and not on hydroxyurea therapy

Sr.no	Authors with year of publication	Mean age (months)	Not on hydroxyurea therapy			On hydroxyurea therapy			Hydroxyurea dose (mg/kg/day)
Sr.no	Authors with year of publication	Mean age (months)	N	Incidence of stroke /100-person year^a	Mean HbF level	N	Incidence of stroke /100-person year	Mean HbF level	Hydroxyurea dose (mg/kg/day)
1	Hankins JS et al. 2008	132	25	2.54	4	18	1.9	18.2	30
2	Wang WC et al. 2001	15	16	10	21.8	14	7.14	20.2	20
3	Nottage KA et al. 2016	113	50	4.04	5	30	1.1	14	20
4	Wang WC et al. 2021	149	19	3.82	8.2	9	11.10	23.1	23.8

Mean incidence rate of stroke in SCD not on hydroxyurea: 5.1, SD 3·3
Mean incidence rate of stoke on hydroxyurea: 5.31, SD 4.6
Unpaired t-test: t = 0.0742 df = 6 standard error of difference = 5.161
The two-tailed P value equals 0.9433
^aMean age of patients is considered as the total duration of non-exposure to hydroxyurea and the person-years is calculated by mean age in years X total number of patients

ISSN: 2046-4053